Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Monotherapy in Type 2 Diabetes (SURPASS-1)
NCT03954834Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at Week 40. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03954834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954834.